Latest Breaking News On - Scandion oncology - Page 1 : comparemela.com

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
bmj.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bmj.com Daily Mail and Mail on Sunday newspapers.

United statesEteläuomen läiSouth koreaJin wangGenentechf hoffmannAsher biotherapeuticsDaiichi sankyoChipscreen biosciencesBristol myers squibbAshfield medcommsMerck biopharmMerck seronoSamsung bioepisLyell immunopharmaCalithera biosciencesEli lilly

SCO-101 Plus FOLFIRI Shows Signs of Efficacy in Metastatic Colorectal Cancer

The combination of SCO-101 and FOLFIRI resulted in tumor reduction and increased progression-free survival in patients with metastatic colorectal cancer.

Francois marteletClinical developmentScandion oncologyColorectal cancer

LIfT BioSciences appoints Dr Bo Rode Hansen and Dr Marco Gottardis to its Board of Directors

LIfT BioSciences appoints Dr Bo Rode Hansen and Dr Marco Gottardis to its Board of Directors

City ofUnited kingdomMary jane elliottMarco gottardisSantaris pharmaLindsey nevilleNamrata taakAlex blythUniversity of wisconsinRoche innovation centre copenhagenColumbia universityOncology discovery group at bristol myers squibbHenley business schoolOncology researchNovo seeds holdingsGenevant sciences

SCO-101 Plus FOLFIRI Provides Survival Benefit in Metastatic Colorectal Cancer

SCO-101 in combination with leucovorin, fluorouracil, and irinotecan (FOLFIRI) provided a clinically meaningful overall survival benefit in heavily pretreated patients with metastatic colorectal cancer who had no other active treatment options available, according to final data from part 2 of the phase 2 CORIST study.

Lars damstrupScandion oncologySco 101Corist study

Colorectal Cancer Treatment Drug Market to Show Immense Growth During the Study Period (2019-2032)

Apart from the already existing players such as Pfizer, Sanofi, Taiho Pharma, Ono Pharma, along with others, there are several emerging key players, that are.

United statesUnited kingdomTreos bioHutchison medipharmaPrnewswire delveinsightDaiichi sankyoSumitomo dainippon pharmaLyell immunopharmaMerck eisaiDaiichi sankyo astrazenecaSalubris biotherapeuticsEli lillyShruti thakurMerck seronoTaiho pharmaBristol myers squibb